

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 58060

Manuscript Type: EDITORIAL

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?

Stavroula Veneti, Konstantinos Tziomalos

Abstract

Chronic kidney disease constitutes a major microvascular complication of diabetes mellitus. Accumulating data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) might have a role in the management of diabetic kidney disease (DKD). GLP-1 RAs appear to reduce the incidence of persistent macroalbuminuria in patients with type 2 diabetes mellitus. This beneficial effect appears to be mediated not only by

Match Overview

1	Internet 24 words crawled on 17-Feb-2020 link.springer.com	2%
2	Internet 24 words crawled on 28-Sep-2019 journals.sagepub.com	2%
3	Internet 22 words crawled on 17-Feb-2020 www.fda.gov	2%
4	Crossref 21 words Salvatore De Cosmo, Francesca Viazzi, Pamela Piscitelli, Giovanna Leoncini et al. "Impact of CVOTs in primary a...	2%
5	Internet 18 words crawled on 01-Nov-2019 academic.oup.com	1%
6	Internet 17 words crawled on 21-Jun-2020 medcraveonline.com	1%
7	Internet 16 words crawled on 24-Aug-2020 dmsjournal.biomedcentral.com	1%
8	Crossref 15 words Marco Castellana, Angelo Cignarelli, Francesco Brescia, Luigi Laviola, Francesco Giorgino. "GLP-1 receptor agoni	1%
9	Internet 14 words crawled on 17-Feb-2020 onlinelibrary.wiley.com	1%
	Internet 14 words	1.0%



Is there a role for glucagon-like peptide-1 receptor agonists in the mana



ALL

IMAGES

VIDEOS

33,300 Results

Any time ▾

Glucagon-like Peptide-1 Receptor Agonists: A Class Update ...

<https://pubmed.ncbi.nlm.nih.gov/28942790>

In this review, I provide a clinical update of **glucagon-like peptide-1 receptor agonists** (GLP-1RAs), a class of incretin-based, injectable antidiabetes therapies which improve fasting and postprandial blood glucose control through glucose-dependent pancreatic islet cell hormone secretion without significant risks for hypoglycemia.

Review of Glucagon-Like peptide-1 Receptor Agonists for ...

<https://pubmed.ncbi.nlm.nih.gov/31318152>

Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD), and when it causes CKD it is collectively referred to as diabetic kidney disease. One of the newer therapies for **managing hyperglycemia** is the glucagon-like peptide-1 receptor agonist (GLP-1RA) drug class.

Review of glucagon-like peptide-1 receptor agonists for ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/1753-0407.12969>

Jul 18, 2019 · Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD), and when it causes CKD it is collectively referred to as **diabetic** kidney disease. One of the newer therapies for managing hyperglycemia is the **glucagon-like peptide-1 receptor agonist** ...

Search Tools

[Turn off Hover Translation \(关闭取词\)](#)

Is there a role for glucagon-like peptide-1 receptor agonists in the m



ALL IMAGES VIDEOS

30,900 Results

Any time ▼

The protective roles of GLP-1R signaling in diabetic ...

<https://pubmed.ncbi.nlm.nih.gov/24152968>

Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone that has an antioxidative protective effect on various tissues. Here, we determined whether GLP-1 has a **role** in the pathogenesis of **diabetic nephropathy** using **nephropathy**-resistant C57BL/6-Akita and **nephropathy**-prone KK/Ta-Akita mice.

Review of glucagon-like peptide-1 receptor agonists for ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/1753-0407.12969>

Jul 18, 2019 · Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD), and when it causes CKD it is collectively referred to as diabetic kidney disease. One of the **newer** therapies for **managing hyperglycemia** is the glucagon-like peptide-1 ...

Cited by: 6

Author: Lance A. Sloan

Publish Year: 2019

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of ...

<https://care.diabetesjournals.org/content/41/11/2330> ▼

Nov 01, 2018 · Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are injectable incretin-based drugs recommended as **second- or third-line treatments in type 2 diabetes** (1). These drugs have been shown to have neutral or favorable risk profiles with regard to cardiovascular outcomes in recent large randomized controlled trials (RCTs) (2 – 5).

Cited by: 6

Author: Antonios Douros, Antonios Douros, Antoni...

Publish Year: 2018

[PDF] Review of Glucagon-Like Peptide-1 Receptor Agonists for ...

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.12969>

with **glucagon-like peptide-1 receptor agonists** (GLP-1RAs), these agents improved glycemic control in patients with mild to moderately impaired kidney function, without significant differences compared with patients with normal renal function. † GLP-1RAs were associated with a lower incidence of **diabetic nephropathy**,

Cited by: 6

Author: Lance A. Sloan

Publish Year: 2019

Glucagon Like Peptide 1 Receptor Agonist - an overview ...

<https://www.sciencedirect.com/.../glucagon-like-peptide-1-receptor-agonist>

Agents for Type 2 Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonists GLP-1 receptor agonists

Glucagon-like peptide-1 receptor agonist

Glucagon-like peptide-1 receptor agonists, also known as GLP-1 receptor agonists or incretin mimetics, are agonists of the GLP-1 receptor. This class of medications is used for the treatment of type 2 diabetes. One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. GLP-1 as has a short duration of action, so to overcome this limitation several modifications either in the drug or the formulations are being developed.




Wikipedia

Data from: Wikipedia

Suggest an edit

Search Tools

Turn off Hover Translation (关闭取词)

Is there a role for glucagon-like peptide-1 receptor agonists in the mana ×  

ALL IMAGES VIDEOS

65,000 Results Any time ▾

[The protective roles of GLP-1R signaling in diabetic ...](#)

<https://pubmed.ncbi.nlm.nih.gov/24152968>

Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone that has an antioxidative protective effect on various tissues. Here, we determined whether GLP-1 has **a role** in the pathogenesis of **diabetic nephropathy** using **nephropathy**-resistant C57BL/6-Akita and **nephropathy**-prone KK/Ta-Akita mice.

[Review of glucagon-like peptide-1 receptor agonists for ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1111/1753-0407.12969>

Jul 18, 2019 · Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD), and when it causes CKD it is collectively referred to as diabetic kidney disease. One of the **newer** therapies for **managing hyperglycemia** is the glucagon-like peptide-1 receptor ...

Cited by: 6

Author: Lance A. Sloan

Publish Year: 2019

[Diabetic nephropathy: newer therapeutic perspectives](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116149>

Aug 23, 2018 · The glucagon-like peptide-1 receptor agonist, liraglutide, **attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients**. Tohoku J Exp Med . 2013; 231 (1):57–61. [PubMed] [Google Scholar]

Cited by: 12

Author: Krishna C. Keri, Naga S. Samji, Samuel ...

Publish Year: 2018

[Glucagon-Like Peptide 1 Receptor Agonists and the Risk of ...](#)

<https://care.diabetesjournals.org/content/41/11/2330> ▾

Nov 01, 2018 · Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are injectable incretin-based drugs recommended as **second- or third-line treatments in type 2 diabetes** (1). These drugs have been shown to have neutral or favorable risk profiles with regard to cardiovascular outcomes in recent large randomized controlled trials (RCTs) (2 – 5).

Cited by: 6

Author: Antonios Douros, Antonios Douros, Anto...

Publish Year: 2018

Search Tools

Turn off Hover Translation (关闭取词)